Management of Immune Checkpoint Inhibitor–Induced Myocarditis

The French Working Group’s Plea for a Pragmatic Approach

Franck Thuny, MD, PhD,a,b Joachim Alexandre, MD, PhD,c Joe-Elie Salem, MD, PhD,d Mariana Mirabel, MD, PhD,e Charles Dolladille, MD,f Alain Cohen-Solal, MD, PhD,f Ariel Cohen, MD, PhD,g Stéphane Ederhy, MD,g Jennifer Cautela, MD,a,b on behalf of the French Working Group of Cardio-Oncology

Immune checkpoint inhibitor (ICI)-induced myocarditis is one of the most serious complications of cancer treatment. Although the incidence is uncommon, physicians should be aware of this potentially life-threatening immune-related adverse event (irAE) because of a potential case-fatality rate that can, in the most severe cases, approach 50% (1). The prevalence of disease may also increase as a result of the exponential rise in the indication and prescription of ICIs.

ICI-induced myocarditis is an autoimmune process targeting the myocardium, similar to cellular rejection in heart transplant recipients. It is caused by restoration of the immune response and up-regulation of CD4+ and CD8+ T cells, which together with macrophages infiltrate and attack myocytes and cardiac conduction tissue (2). Whereas the reported incidence of cardiovascular irAEs was very low in the first trials to study the efficacy of ICIs in melanoma and lung cancers, myocarditis has subsequently emerged as a life-threatening condition, described first in case reports and then in larger case series (1–3). In the Bristol Myers Squibb safety databases, the initial incidence estimates of ICI-induced myocarditis ranged from 0.06% for monotherapy to 0.27% for combination therapy (2). This incidence was most likely underestimated, considering the lack of a systematic screening policy or well-defined diagnostic criteria for myocarditis when these first therapeutic trials were conducted; it is plausible that several cases of myocarditis were undiagnosed. Subsequent cohorts of patients treated with ICIs have suggested an incidence of myocarditis ranging from 1% to 2%, often occurring early after treatment initiation, following the first few cycles (1).

Patients with ICI-induced myocarditis may not have any prior cardiovascular symptoms or signs, and the first manifestation can be a serious cardiac complication; they are at high risk of ventricular arrhythmias and atrioventricular block despite an often preserved left ventricular ejection fraction (1–3). The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center.
or rise in troponin level should trigger a cardio-oncology consult. Treatment consists of the discontinuation of ICIs, administration of high doses of corticosteroids as first-line therapy, and intensified immunosuppressive therapy initiated as soon as there is indication of an unfavorable clinical course. U.S. and European guidelines on the diagnosis and management of ICI-associated irAEs have been published recently (4–6). However, the relatively low level of evidence supporting these recommendations has led to numerous discrepancies, leaving clinicians without a consensus strategy to follow.
Regarding the screening strategy for ICI-induced myocarditis, the guidelines recommend that baseline electrocardiography, troponin, and natriuretic peptides testing should be evaluated before starting ICI therapy (especially in patients treated with combination ICIs) (5,6). Whereas some guidelines recommend repeating this evaluation before each infusion in patients treated with combination ICI (6), others recommend that this should be based on the occurrence of cardiovascular symptoms or signs or if non-cardiovascular irAEs occur (5).

On suspicion of ICI-induced myocarditis, the guidelines emphasize that work-up should include troponin and natriuretic peptides testing, a trans-thoracic echocardiogram, cardiovascular magnetic resonance imaging, and endomyocardial biopsy when possible (4–6). Nevertheless, the diagnosis of ICI-induced myocarditis may not be easy to establish given the frequently normal results in the early phase of the disease. One report suggested normal cardiovascular magnetic resonance findings in up to 70% of patients when performed within 4 days of admission (7). Furthermore, endomyocardial biopsy is not available in all centers. Case reports have suggested a potential role of other imaging modalities such as positron emission tomography. Recently, diagnostic criteria have been published, leading to the classification of ICI-induced myocarditis as definite, probable, or possible based on the results of clinical, biological, and imaging investigations (8). This classification has yet to be validated in a clinical study.

Regarding the management of patients with a clinical suspicion of ICI-induced myocarditis, guidelines recommend immediate withholding of ICI treatment, urgent admission into a coronary (or intensive) care unit, and prompt investigations to confirm or rule out the diagnosis of myocarditis without delaying the introduction of high-dose corticosteroid treatment. Although early initiation of corticosteroids is associated with improved cardiac outcomes, it remains unclear which treatment should be used when the patient’s clinical condition deteriorates despite corticosteroid therapy. According to the disease pathophysiology, it is currently recommended to use therapies similar to those prescribed for acute cellular rejection in transplanted hearts. Nevertheless, this strategy is empiric, and recent case series have suggested the efficacy of drugs such as tocilizumab, abatacept, alemtuzumab, or tofacitinib. Furthermore, the clinical criteria that should lead to the intensification of the immunosuppressive therapy have yet to be precisely defined by further studies.

Regarding the decision on whether to rechallenge ICI therapy, only the American Society of Clinical Oncology guidelines have addressed this issue, and recommend to permanently discontinue ICI treatment regardless of the severity of myocarditis (grades 1 to 4) (6). This recommendation is based on expert opinion.
consensus and the perceived concern that recurrence would be fatal. On the one hand, clinical trials have demonstrated that patients with noncardiovascular irAEs may have favorable clinical outcomes even after ICI discontinuation (6). Thus, many patients with ongoing stable or responding disease may not need an ICI rechallenge as maintenance therapy. On the other hand, case reports have suggested that a rechallenge might be tolerated in cases of mild irAEs, including low-grade myocarditis.

The low level of evidence supporting the management of ICI-induced myocarditis has not resulted in clear decisional algorithms in the recent guidelines; in our view, clinicians would benefit from pragmatic recommendations to help guide them in their daily practice.

In the face of an uncommon, fatal, but curable disease, should we wait for more evidence before proposing a rapid and standardized management strategy? This question is certainly relevant to ICI-induced myocarditis. We urgently need management protocols—ones that should be updated as knowledge evolves and that should be tailored to specific situations. For now, pending the availability of a higher level of evidence from randomized trials, we have to rely on observational studies and the experience from high-volume centers. A number of screening protocols, based on local expertise, have been suggested.

In an effort to comprehensively harmonize the current guidelines, the French Working Group of Cardio-Oncology recently proposed a different approach (10). This expert panel consisted of cardiologists, oncologists, hematologists, and pharmacologists, who lead regional cardio-oncology programs involved in the daily management of patients with cancer therapy-induced cardiovascular toxicity. The panel analyzed and compared the key components of the pathways recommended in the most recent guidelines from the U.S. and European societies of both oncology and cardiology, then harmonized these consensus statements into practical roadmaps that we feel can be adapted by clinicians for use in daily practice (Figure 1). We fully acknowledge that this is not based on stronger evidence than that used to establish the guidelines, and it will have to be updated regularly in response to emerging evidence from future studies.

The increasing prescription of ICIs makes it imperative to provide new data to address the following issues related to ICI-induced myocarditis: 1) What are the clinical, biological, and imaging predictors of this complication? 2) Are there predisposing genetic factors? 3) Is it possible to establish a preventive strategy? 4) What are the predictors of poor prognosis? 5) What is the best immunosuppressive therapeutic strategy? 6) Is it possible to rechallenge ICIs in some patients after an episode of myocarditis?

Knowledge of the cardiovascular toxicity associated with cancer immune therapies is increasing, but many uncertainties remain. Cardiologists and oncologists urgently need practical management protocols, which will need to be updated regularly as research and our understanding evolves.

FUNDING SUPPORT AND AUTHOR DISCLOSURES

Dr. Thuny has received modest fees for lectures outside the submitted work from Merck Sharp and Dohme, Bristol Myers Squibb, and Roche. Dr. Alexandre has received modest lecture fees outside the submitted work from Bristol Myers Squibb. Dr. Salem has received modest fees for serving on advisory boards from Bristol Myers Squibb; and shares a patent related to the use of CTLA4 agonists for the treatment of severe immune-related adverse reactions. Dr. Cohen has received modest consultant and lecture fees outside the submitted work from Bristol Myers Squibb. Dr. Ederhy has received modest lecture fees outside the submitted work from Bristol Myers Squibb. Dr. Cautela has received modest lecture fees outside the submitted work from Merck Sharp and Dohme. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

ADDRESS FOR CORRESPONDENCE: Dr. Franck Thuny, University Mediterranean Center of Cardio-Oncology, Unit of Heart Failure and Valvular Heart Diseases, North Hospital, Aix-Marseille University, Chemin des Bourrely, 13015 Marseille, France. E-mail: franck.thuny@gmail.com. Twitter: @franckthuny, @CautelaJennifer, @unico_greco.
patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018;36:1714–68.

6. Pudil R, Mueller C, Celutkiene J, et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail 2020;22:1966–83.

7. Zhang L, Awadalla M, Mahmood SS, et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J 2020;41:1733–43.

8. Bonaca MP, Olenchock BA, Salem J-E, et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation 2019;140:80–91.

9. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015;372:2006–17.

10. Alexandre J, Cautela J, Ederhy S, et al. Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the American and European Cardio-Oncology Guidelines. J Am Heart Assoc 2020;9:e018483.

KEY WORDS cancer, immune checkpoint inhibitors, myocarditis